Brind.
From Adial Pharmaceuticals appoints David Rubenstein as Chief Scientist

How could the development of AT177 affect the Center for Drug Evaluation and Research?

Possible What happens if… A possibility worth considering, not a forecast.

Adial's new drug development could engage FDA's drug evaluation center The development of AT177, a proprietary, oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist for ulcerative colitis, requires navigating the U.S. regulatory pathway. With David Rubenstein leading the scientific strategy, the drug is currently in IND-enabling studies, with clinical trials planned for 2027. As a specialized research center within the FDA, the Center for Drug Evaluation and Research is responsible for guiding and reviewing the scientific and clinical data of novel drug candidates like AT177 as they move toward regulatory approval.

Reported by 1 independent outlet Written Oct 16
Effect
Mixed
How direct
Brind's reasoning
When
Within months
The story
Gone quiet

How it reaches Center for Drug Evaluation and Research

Reported by news outletsBrind's reasoning

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

  • David Rubenstein was Chief Scientific Officer of Dermavant Sciences, which approved tapinarof, the first AhR agonist, for plaque psoriasis and atopic dermatitis.manilatimes.net
  • Adial Pharmaceuticals' lead program, AT177, is a proprietary, oral, colon-targeted AhR agonist for ulcerative colitis.manilatimes.net
  • AT177 is currently in IND-enabling studies, with clinical trials planned for 2027.manilatimes.net

Why it matters

For Adial Pharmaceuticals, the success of AT177 hinges on successfully completing IND-enabling studies and gaining regulatory approval. The appointment of David Rubenstein, who has successfully navigated the regulatory path for a similar AhR agonist, is intended to de-risk this process and accelerate the company's ability to bring a new oral treatment to patients with ulcerative colitis.

For the Center for Drug Evaluation and Research, the progression of AT177 represents a specific case study in the evaluation of novel AhR agonists. The center's role is to ensure that the scientific data supporting the drug's mechanism and safety—particularly its colon selectivity—meets the rigorous standards required for U.S. market access.

What we don't know yet

  • What specific regulatory guidance will the Center for Drug Evaluation and Research provide regarding AT177's colon selectivity?
  • How will the IND-enabling studies progress toward the planned 2027 clinical trials?

What would change this answer

AT177 successfully completes preclinical studies demonstrating robust local colonic AhR activation with limited systemic exposure.This strong data would likely streamline the regulatory review process, potentially increasing the speed and certainty of the Center for Drug Evaluation and Research's engagement.
The FDA requires significant additional data or modifications to the IND-enabling program.This would extend the timeline and increase the complexity of the Center for Drug Evaluation and Research's oversight role.

— Other considerations

Beyond this explainer

Questions worth asking

Ideas the web ties closely to this story that the explainer doesn't mention. These are prompts for your own research: Brind hasn't answered them.

  • About Clinical Remission

    Since AT177 is being developed for ulcerative colitis, what specific clinical endpoints, such as achieving clinical remission, will CDER prioritize during its evaluation?

  • About Crohns

    Given that AT177 is designed for ulcerative colitis, does the drug's colon selectivity suggest it might also be relevant for treating Crohn's disease?

  • About Constitutive Activity

    Since AT177 is an AhR agonist, how will CDER evaluate the safety implications of its constitutive activity in the colon?

Explore connected ideas

Each opens in Related concepts: what the web connects to it, with Brind's news on it.

The ideas come from how millions of web pages place them near each other. The questions are Brind's AI reasoning, written only from this explainer and Brind's own reporting.

Who else could feel it

Other possible ripples from the same event.

Reporting

Keep going

The full eventAdial Pharmaceuticals appoints David Rubenstein as Chief Scientist Everything aboutCenter for Drug Evaluation and Research

Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.